{"id":46079,"date":"2022-07-12T17:01:35","date_gmt":"2022-07-12T15:01:35","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/vital-blood-plasma-production-more-than-doubled-major-project-by-zeta-group\/"},"modified":"2022-07-12T17:01:35","modified_gmt":"2022-07-12T15:01:35","slug":"vital-blood-plasma-production-more-than-doubled-major-project-by-zeta-group","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/vital-blood-plasma-production-more-than-doubled-major-project-by-zeta-group\/","title":{"rendered":"Vital Blood Plasma Production More Than Doubled: Major Project by ZETA Group"},"content":{"rendered":"
\n

GRAZ, Austria–(BUSINESS WIRE)–Blood plasma forms the basis of many life-saving therapies and is also an important building block for future active ingredients in medical research. As the general planner for <\/b>Octapharma,<\/b><\/a> <\/b>ZETA<\/b><\/a> implemented an industry leading EPCM project resulting in the doubling of plasma throughput at the Vienna, Austria manufacturing site.<\/b>\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe pharmaceutical industry relies on ZETA’s many years of experience in production processes and solutions for life-saving blood plasma products. ZETA’s extensive biopharmaceutical expertise in the areas of precipitation, centrifugation and mixing is in high demand, as is the gentle thawing of protein solutions. Octapharma, a leading global producer of human protein products, expanded its plasma fractionation production facilities in Vienna, Austria. As the manufacturer’s general planner, ZETA led the major project to success: The plasma throughput has more than doubled in two expansion steps. In the first step an additional new manufacturing building was constructed, while in the second step, the new equipment was integrated with the existing production.\n<\/p>\n

\nComprehensive expertise in turnkey project management<\/b>\n<\/p>\n

\nOctapharma relied on ZETA’s extensive planning and project management expertise and opted for implementation based on the full EPCM (Engineering, Procurement and Construction Management) model. \u201cWe worked successfully with ZETA on other large projects and because of our positive experience, we entrusted ZETA with the general planning,\u201d stated Production Manager Albin Hauler, Octapharma, regarding the first-class collaboration.\n<\/p>\n

\nThe heart of the project, the blood plasma processing plant, was planned and constructed directly by ZETA. As the general planner, ZETA was also responsible for all essential planning phases and the coordination of the trades involved. The spectrum included structural planning, construction, clean room, HVAC, electrical engineering, black media supply, fire protection and EMS\/BMS. As the actual builder, as well as the general planner, ZETA demonstrates unparalleled expertise for complex turnkey projects.\n<\/p>\n

\nScheduling to keep vital processes running<\/b>\n<\/p>\n

\nA central requirement was to keep the current plasma production running on the existing systems, while implementing and integrating the new construction site. \u201cAs with all projects, strict adherence to the schedule is essential. ZETA always met our schedule and used the planned shutdown times to integrate the new equipment and processes into the existing production,\u201d said Gerhard Gatterwe, Project Manager, Octapharma.\n<\/p>\n

\nTrusted partner for the global biopharmaceutical industry<\/b>\n<\/p>\n

\nZETA\u2019s expertise could be in demand again as several important follow-up projects for further expansion are planned. \u201cMutual trust is high and the success of the Octapharma project is ultimately the greatest proof. We look forward to a successful future together,\u201d says Johannes Koch, Associate Director Engineering, ZETA Group.\n<\/p>\n

\nAbout ZETA<\/b>\n<\/p>\n

\nWith over 1200 highly qualified employees and 27 subsidiaries worldwide, ZETA specializes in planning, automation, digitalization, and maintenance of customized biopharmaceutical facilities for aseptic process solutions. ZETA is a one-stop-shop biomanufacturer, combining plant engineering and automation with HVAC and cleanroom design.\n<\/p>\n

\nZETA is actively taking steps toward a more environmentally-friendly future for the entire industry. With ZETA’s well-designed decarbonization and sustainability strategies, reduced carbon emissions and energy efficiencies can be achieved in biomanufacturing processes and facilities.\n<\/p>\n

\nBiopharmaceutical active ingredients, such as anti-cancer drugs, insulin, vaccines, and infusions, are produced in these highly complex, “tailor-made” facilities. ZETA supports its customers across the entire drug development and manufacturing pathway with sophisticated solutions from the laboratory to industrial production scale. Through its Smart Engineering Services, ZETA creates digital twins of process plants and is a market leader for digital solutions in the pharmaceutical and biotech industry.\n<\/p>\n

\nMore info about the project.<\/a>\n<\/p>\n

\nwww.zeta.com<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nPress Contact<\/b>
Andreas Pompenig<\/b>
Teamleader Communication
\n
+43 (664) 808 52 1424
\n
andreas.pompenig@zeta.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

GRAZ, Austria–(BUSINESS WIRE)–Blood plasma forms the basis of many life-saving therapies and is also an important building block for future active ingredients in medical research. As the general planner for Octapharma, ZETA implemented an industry leading EPCM project resulting in the doubling of plasma throughput at the Vienna, Austria manufacturing site. The pharmaceutical industry relies … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46079","6":"format-standard","7":"category-industry"},"yoast_head":"\nVital Blood Plasma Production More Than Doubled: Major Project by ZETA Group - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/vital-blood-plasma-production-more-than-doubled-major-project-by-zeta-group\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vital Blood Plasma Production More Than Doubled: Major Project by ZETA Group - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"GRAZ, Austria–(BUSINESS WIRE)–Blood plasma forms the basis of many life-saving therapies and is also an important building block for future active ingredients in medical research. As the general planner for Octapharma, ZETA implemented an industry leading EPCM project resulting in the doubling of plasma throughput at the Vienna, Austria manufacturing site. The pharmaceutical industry relies ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/vital-blood-plasma-production-more-than-doubled-major-project-by-zeta-group\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-12T15:01:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220712005100\/en\/1509204\/21\/ZETA_Octapharma_Blood_Plasma_Business_Wire.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vital-blood-plasma-production-more-than-doubled-major-project-by-zeta-group\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vital-blood-plasma-production-more-than-doubled-major-project-by-zeta-group\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Vital Blood Plasma Production More Than Doubled: Major Project by ZETA Group\",\"datePublished\":\"2022-07-12T15:01:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vital-blood-plasma-production-more-than-doubled-major-project-by-zeta-group\\\/\"},\"wordCount\":604,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vital-blood-plasma-production-more-than-doubled-major-project-by-zeta-group\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220712005100\\\/en\\\/1509204\\\/21\\\/ZETA_Octapharma_Blood_Plasma_Business_Wire.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vital-blood-plasma-production-more-than-doubled-major-project-by-zeta-group\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vital-blood-plasma-production-more-than-doubled-major-project-by-zeta-group\\\/\",\"name\":\"Vital Blood Plasma Production More Than Doubled: Major Project by ZETA Group - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vital-blood-plasma-production-more-than-doubled-major-project-by-zeta-group\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vital-blood-plasma-production-more-than-doubled-major-project-by-zeta-group\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220712005100\\\/en\\\/1509204\\\/21\\\/ZETA_Octapharma_Blood_Plasma_Business_Wire.jpg\",\"datePublished\":\"2022-07-12T15:01:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vital-blood-plasma-production-more-than-doubled-major-project-by-zeta-group\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vital-blood-plasma-production-more-than-doubled-major-project-by-zeta-group\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vital-blood-plasma-production-more-than-doubled-major-project-by-zeta-group\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220712005100\\\/en\\\/1509204\\\/21\\\/ZETA_Octapharma_Blood_Plasma_Business_Wire.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220712005100\\\/en\\\/1509204\\\/21\\\/ZETA_Octapharma_Blood_Plasma_Business_Wire.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vital-blood-plasma-production-more-than-doubled-major-project-by-zeta-group\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vital Blood Plasma Production More Than Doubled: Major Project by ZETA Group\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vital Blood Plasma Production More Than Doubled: Major Project by ZETA Group - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/vital-blood-plasma-production-more-than-doubled-major-project-by-zeta-group\/","og_locale":"en_US","og_type":"article","og_title":"Vital Blood Plasma Production More Than Doubled: Major Project by ZETA Group - Pharma Trend","og_description":"GRAZ, Austria–(BUSINESS WIRE)–Blood plasma forms the basis of many life-saving therapies and is also an important building block for future active ingredients in medical research. As the general planner for Octapharma, ZETA implemented an industry leading EPCM project resulting in the doubling of plasma throughput at the Vienna, Austria manufacturing site. The pharmaceutical industry relies ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/vital-blood-plasma-production-more-than-doubled-major-project-by-zeta-group\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-12T15:01:35+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220712005100\/en\/1509204\/21\/ZETA_Octapharma_Blood_Plasma_Business_Wire.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/vital-blood-plasma-production-more-than-doubled-major-project-by-zeta-group\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/vital-blood-plasma-production-more-than-doubled-major-project-by-zeta-group\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Vital Blood Plasma Production More Than Doubled: Major Project by ZETA Group","datePublished":"2022-07-12T15:01:35+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/vital-blood-plasma-production-more-than-doubled-major-project-by-zeta-group\/"},"wordCount":604,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/vital-blood-plasma-production-more-than-doubled-major-project-by-zeta-group\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220712005100\/en\/1509204\/21\/ZETA_Octapharma_Blood_Plasma_Business_Wire.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/vital-blood-plasma-production-more-than-doubled-major-project-by-zeta-group\/","url":"https:\/\/pharma-trend.com\/en\/vital-blood-plasma-production-more-than-doubled-major-project-by-zeta-group\/","name":"Vital Blood Plasma Production More Than Doubled: Major Project by ZETA Group - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/vital-blood-plasma-production-more-than-doubled-major-project-by-zeta-group\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/vital-blood-plasma-production-more-than-doubled-major-project-by-zeta-group\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220712005100\/en\/1509204\/21\/ZETA_Octapharma_Blood_Plasma_Business_Wire.jpg","datePublished":"2022-07-12T15:01:35+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/vital-blood-plasma-production-more-than-doubled-major-project-by-zeta-group\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/vital-blood-plasma-production-more-than-doubled-major-project-by-zeta-group\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/vital-blood-plasma-production-more-than-doubled-major-project-by-zeta-group\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220712005100\/en\/1509204\/21\/ZETA_Octapharma_Blood_Plasma_Business_Wire.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220712005100\/en\/1509204\/21\/ZETA_Octapharma_Blood_Plasma_Business_Wire.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/vital-blood-plasma-production-more-than-doubled-major-project-by-zeta-group\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Vital Blood Plasma Production More Than Doubled: Major Project by ZETA Group"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46079","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46079"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46079\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46079"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46079"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46079"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}